Biocept (BIOCQ) 10-Q 10 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	1,044,378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,499,397

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 678,855	$ 8,821,329
Accounts receivable	85,664	34,200
Inventories, net	497,517	349,271
Prepaid expenses and other current assets	499,133	435,938
Total current assets	1,761,169	9,640,738
Fixed assets, net	1,521,380	946,180
Total assets	3,282,549	10,586,918
Current liabilities:
Accounts payable	1,700,383	632,538
Accrued liabilities	1,143,863	966,899
Supplier financings	48,880	42,369
Current portion of equipment financings	255,605	110,924
Current portion of credit facility	1,896,718	1,588,058
Total current liabilities	5,045,449	3,340,788
Non-current portion of equipment financings, net	572,096	291,189
Non-current portion of credit facility, net	1,593,220	2,638,487
Non-current portion of interest payable	209,914	153,547
Non-current portion of deferred rent	418,028	470,172
Total liabilities	7,838,707	6,894,183
Commitments and contingencies (see Note 11)
Shareholders’ equity/(deficit):
Common stock, $0.0001 par value, 40,000,000 authorized; 6,556,685 issued and outstanding at December 31, 2015; 150,000,000 authorized; 8,399,397 issued and outstanding at September 30, 2016.	840	656
Additional paid-in capital	164,891,998	158,928,627
Accumulated deficit	(169,448,996)	(155,236,548)
Total shareholders’ equity/(deficit)	(4,556,158)	3,692,735
Total liabilities and shareholders’ equity/(deficit)	$ 3,282,549	$ 10,586,918

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	40,000,000
Common stock, shares issued	8,399,397	6,556,685
Common stock, shares outstanding	8,399,397	6,556,685

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenues:	$ 1,047,280	$ 164,856	$ 1,931,509	$ 391,626
Costs and expenses:
Cost of revenues	1,876,288	1,159,710	5,020,649	3,320,467
Research and development expenses	600,613	677,729	2,044,968	2,073,391
General and administrative expenses	1,919,843	1,630,608	4,924,731	4,281,883
Sales and marketing expenses	1,278,455	1,055,653	3,875,063	2,616,218
Total costs and expenses	5,675,199	4,523,700	15,865,411	12,291,959
Loss from operations	(4,627,919)	(4,358,844)	(13,933,902)	(11,900,333)
Other income/(expense):
Interest expense, net	(154,869)	(175,562)	(393,029)	(494,235)
Other income	38,412	38,412	115,236	64,020
Gain on sale of fixed assets	1,300		1,300
Total other income/(expense):	(115,157)	(137,150)	(276,493)	(430,215)
Loss before income taxes	(4,743,076)	(4,495,994)	(14,210,395)	(12,330,548)
Income tax expense		(199)	(2,053)	(1,478)
Net loss and comprehensive loss	$ (4,743,076)	$ (4,496,193)	$ (14,212,448)	$ (12,332,026)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	8,370,691	6,242,604	7,549,663	5,245,303
Diluted	8,370,691	6,242,604	7,549,663	5,245,303
Net loss per common share:
Basic	$ (0.57)	$ (0.72)	$ (1.88)	$ (2.35)
Diluted	$ (0.57)	$ (0.72)	$ (1.88)	$ (2.35)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows from Operating Activities:
Net loss	$ (14,212,448)	$ (12,332,026)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	248,164	188,120
Inventory reserve	(40,708)	(20,277)
Stock-based compensation	1,164,979	1,016,266
Non-cash interest expense related to credit facility and other financing activities	60,951	93,454
Gain on sale of fixed assets	(1,300)
Increase/(decrease) in cash resulting from changes in:
Accounts receivable	(51,464)	(29,760)
Inventories	(107,538)	(93,000)
Prepaid expenses and other current assets	501,532	(181,284)
Accounts payable	991,846	142,028
Accrued liabilities	152,860	218,468
Accrued interest	58,684	96,295
Deferred rent	(22,839)	5,614
Net cash used in operating activities	(11,257,281)	(10,896,102)
Cash Flows from Investing Activities:
Proceeds from sale of fixed assets	1,300
Purchases of fixed assets	(392,496)	(118,896)
Net cash used in investing activities	(391,196)	(118,896)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants	4,798,576	8,830,057
Proceeds from exercise of common stock warrants		9,697,660
Payments on equipment financings	(86,336)	(54,007)
Payments on supplier and other third party financings	(427,934)	(33,674)
Payments on line of credit	(778,303)	(247,701)
Net cash provided by financing activities	3,506,003	18,192,335
Net increase (decrease) in Cash and Cash Equivalents	(8,142,474)	7,177,337
Cash and Cash Equivalents at Beginning of Period	8,821,329	5,364,582
Cash and Cash Equivalents at End of Period	678,855	12,541,919
Cash paid during the period for:
Interest	282,142	309,324
Taxes	$ 2,053	$ 2,054

Condensed Statements of Cash F6

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Warrants to purchase common stock, period			5 years
Purchase of common stock by underwriters to cover overallotments, grant date fair value			$ 7,700,000
Overallotment issued to underwriter to purchase common stock, period			45 days
Common shares issuable to underwriters under granted option			400,000
Purchase of common stock by underwriters to cover overallotments, per share	$ 3.75		$ 3.75
Common Shares issuable to underwriters under warrants granted			400,000
Common stock, par value	$ 0.0001		$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value			$ 1,600,000
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs		$ 63,111
Fixed assets purchased under capital lease obligations			631,232	$ 279,008
Fixed assets with a remaining net book value under capital lease obligations			126,811
Purchases of fixed assets			8,637	3,190	$ 64,300	$ 19,546
Financed insurance premium through third party financing			$ 434,475
Proceeds from exercise of common stock warrants				$ 9,697,660
Roth Capital Partners, LLC and Feltl [Member]
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs	$ 130,252
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs paid net	$ 0
Overallotment Options [Member]
Common stock, par value	$ 0.0003		$ 0.0003

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended September 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

Liquidity and Going Concern Unc

Liquidity and Going Concern Uncertainty	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Liquidity and Going Concern Uncertainty	2. Liquidity and Going Concern Uncertainty As of September 30, 2016, cash and cash equivalents totaled $0.7 million and the Company had an accumulated deficit of $169.4 million. For the year and nine month periods ended December 31, 2015 and September 30, 2016, the Company incurred net losses of $16.9 million and $14.2 million, respectively. At September 30, 2016, the Company had aggregate gross interest-bearing indebtedness of approximately $5.3 million, of which approximately $2.2 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to approximately $2.8 million of other non-interest bearing liabilities. Additionally, in February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly installments of $62,500 through May 2020 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. Subsequent to the closing of a follow-on public offering on February 13, 2015, cash proceeds of approximately $9.8 million have been received by the Company from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $4.68 per share until their expiration in February 2020. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.3 million (see Note 3). Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million (see Note 13). Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

Sales of Equity Securities

Sales of Equity Securities	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Sales of Equity Securities Disclosure [Text Block]	3. Sales of Equity Securities Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis Capital Corp. and Feltl and Company, Inc., as underwriters named therein, a public offering of 2,666,666 shares of the Company’s common stock and warrants to purchase up to an aggregate of 2,666,666 shares of common stock was effected at a combined offering price of $3.75. The estimated grant date fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. All warrants sold in this offering In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 1,662,191 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to Roth Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.3 million after deducting an estimated $0.3 million of additional third party costs incurred in connection with this offering. An aggregate balance of approximately $0.7 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. On November 4, 2016, the Company voluntarily terminated this common stock purchase agreement (see Note 13). Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million (see Note 13).

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments. Other Fair Value Measurements As of the closing of the Company’s public offering in May 2016, the estimated grant date fair value of $1.72 per share associated with the warrants to purchase 1,163,526 shares of common stock issued in such offering, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 2.70 Exercise price $ 3.90 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.23 % Expected life (in years) 5.00 Expected volatility 90.0 % The estimated fair value of the April 2014 Credit Facility at September 30, 2016 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

Balance Sheet Details

Balance Sheet Details	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details: December 31, September 30, 2015 2016 Fixed Assets Machinery and equipment $ 2,518,158 $ 2,707,601 Furniture and office equipment 143,726 143,726 Computer equipment and software 577,898 617,802 Leasehold improvements 514,614 517,968 Financed equipment 914,179 1,457,377 Construction in process 70,815 118,280 4,739,390 5,562,754 Less accumulated depreciation and amortization 3,793,210 4,041,374 Total fixed assets, net $ 946,180 $ 1,521,380 Accrued Liabilities Accrued interest $ 28,981 $ 23,825 Accrued payroll 128,753 301,988 Accrued vacation 307,845 313,825 Accrued bonuses 376,100 318,237 Accrued sales commissions 76,574 97,844 Current portion of deferred rent 31,170 60,475 Accrued other 17,476 27,669 Total accrued liabilities $ 966,899 $ 1,143,863

April 2014 Credit Facility

April 2014 Credit Facility	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid. On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment required the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final payment of $50,000 to the lender. If on or before September 30, 2016 the Company received unrestricted net cash proceeds of at least $7.0 million from the issuance and sale its equity securities, or the Company received a signed letter of intent relating to a sale or merger of the Company, in form and substance satisfactory to the lender, the Company could have been required to make interest-only payments on the term loan through December 31, 2016, and the amount of the additional final payment to the lender upon repayment would have increased to $75,000, which did not occur. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the Company’s 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000. A warrant to purchase up to 17,655 shares of the Company’s common stock at an exercise price of $14.16 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The effective annual interest rate associated with the April 2014 Credit Facility was 11.50% and 13.87% at December 31, 2015 and September 30, 2016, respectively.

Capital Lease Obligations

Capital Lease Obligations	9 Months Ended
	Sep. 30, 2016
Capital Lease Obligations [Abstract]
Capital Lease Obligations	7. Capital Lease Obligations The Company leases certain laboratory equipment under arrangements classified as capital leases. The leased equipment is depreciated on a straight-line basis over periods ranging from 5 to 7 years. Total gross value of fixed assets capitalized under such lease arrangements was $914,179 and $1,457,377 at December 31, 2015 and September 30, 2016, respectively. Total accumulated depreciation related to the leased equipment was approximately $523,000 and $616,000 at December 31, 2015 and September 30, 2016, respectively. Total depreciation expense for the leased equipment was approximately $24,000 and $40,000 for the three months ended September 30, 2015 and 2016, respectively, and was approximately $49,000 and $93,000 for the nine months ended September 30, 2015 and 2016, respectively. The weighted average effective annual interest rates related to the lease obligations are 13.35% and the maturity dates on outstanding arrangements range from July 2017 to May 2023. The following schedule sets forth the future minimum lease payments, as well as corresponding laboratory equipment maintenance obligations that are not recorded as part of the leased equipment balances within fixed assets or capital lease obligations, outstanding under capital leases and due within each respective year ending December 31, and the present value of the minimum lease payments as of September 30, 2016: Minimum Maintenance Lease Obligation Payments Payments 2016 $ 68,754 $ 6,375 2017 238,287 25,440 2018 190,333 25,434 2019 155,388 24,676 2020 151,400 24,608 Thereafter 374,005 59,471 Total payments 1,178,167 166,004 Less amount representing interest 350,466 — Present value of payments $ 827,701 $ 166,004 At September 30, 2016, the present value of minimum lease payments due within one year was $255,605.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	8. Stock-based Compensation On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The following per share amounts and share numbers have been adjusted for this reverse stock split as if it had occurred on January 1, 2015. Equity Incentive Plans The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 1,000,000 shares on a pre-reverse stock split basis, or 333,333 shares on a post-reverse stock split basis, of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. In conjunction with the one-for-three reverse split of the Company’s common stock effected on September 27, 2016, the number of non-inducement shares authorized under all plans decreased from 3,068,865 to 1,022,955 shares, and the number of inducement shares authorized under the 2013 Plan decreased from 1,000,000 shares to 333,333 shares. As of September 30, 2016, under all plans, a total of 1,022,955 non-inducement shares were authorized for issuance, 978,358 non-inducement stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 3,115 non-inducement shares were available for grant. As of September 30, 2016, a total of 333,333 inducement shares were authorized for issuance, 124,999 inducement stock options and RSUs had been issued and were outstanding, and 208,334 inducement shares were available for grant under the 2013 Plan. Stock Options A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Vested and unvested expected to vest, December 31, 2015 646,900 $ 15.48 9.0 Outstanding at December 31, 2015 713,659 $ 11.23 9.0 Granted 276,628 $ 2.60 Exercised — Cancelled/forfeited/expired (63,679 ) $ 8.08 Outstanding at September 30, 2016 926,608 $ 8.87 8.7 Vested and unvested expected to vest, September 30, 2016 838,037 $ 9.37 8.1 The intrinsic values of options outstanding and options vested and unvested expected to vest at September 30, 2016 were both zero. The intrinsic value of options exercisable at September 30, 2016 was zero. The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions: Stock and exercise prices $1.57 - $4.02 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 0.99% – 1.39% Expected life (in years) 5.13 – 6.08 Expected volatility 80.0% - 90.0% Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the nine months ended September 30, 2016 was $1.86 per share. On August 31, 2015, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $4.40 per share to its Chief Executive Officer pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $2.87 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows: Percentage of Overall Stock Option Grants Subject to Vesting Target Minimum number of accessions processed, billed and collected 13 % Minimum revenues from contracts with pharmaceutical companies 10 % Attainment of a sustainable positive GAAP gross margin 12 % Minimum operating cash on-hand with no more than one interim dilutive equity financing event 15 % Achievement of the Company's 2016 corporate goals 25 % Completion of a Board-approved strategic transaction 25 % Total 100 % On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, on July 29, 2016 the CFO was granted inducement stock option awards to purchase up to (i) 66,666 shares of the Company’s common stock with an estimated grant date fair value of $1.45 per share, 25% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which will vest in equal monthly installments over the following three years, and (ii) 33,333 shares of the Company’s common stock with an estimated grant date fair value of $1.26 per share, which vest upon the Company’s achievement of specified corporate goals for 2016 and the consummation of a specified financing transaction. Restricted Stock A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows: Weighted Number of Average Grant Shares Date Fair Value Vested and unvested expected to vest, December 31, 2015 15,369 $ 14.49 Outstanding at December 31, 2015 25,752 $ 15.12 Granted 165,829 $ 1.96 Vested and issued (4,449 ) $ 16.05 Forfeited (10,383 ) $ 16.05 Outstanding at September 30, 2016 176,749 $ 2.70 Vested and unvested expected to vest, September 30, 2016 172,550 $ 2.71 The RSUs granted during the nine months ended September 30, 2016 vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. At September 30, 2016, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $277,496 and $270,904, respectively. On June 12, 2014, the Company’s Board of Directors granted an RSU award for 14,832 shares with a grant date fair value of $16.05 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows: Percentage of Overall RSU Grant Subject to Vesting Target Minimum revenue 25 % Maximum EBITDA loss 15 % Attainment of financial plan for fiscal 2015 20 % Minimum value of strategic agreements 20 % Implementation of four new diagnostic test panels 20 % Total 100 % During the nine months ended September 30, 2016, a total of 4,449 RSUs were declared vested by the Company’s Board of Directors and issued to its Chief Executive Officer in satisfaction of this award and the remaining 10,383 shares underlying this RSU were forfeited. On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 58,332 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 25,000 shares of common stock to its Chief Executive Officer. Each of these retention RSUs has a grant date fair value of $1.86 per share for a grant date fair value of $108,498 to all three officers, in aggregate. These retention RSUs vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. Pursuant to the terms of the Company’s employment agreement with its CFO dated July 25, 2016, the CFO was granted an inducement RSU award on July 29, 2016 covering 25,000 shares of the Company’s common stock with a grant date fair value of $1.95 per share, 100% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the nine months ended September 30, September 30, 2015 2016 2015 2016 Stock Options Cost of revenues $ 15,029 $ 34,119 $ 48,839 $ 89,606 Research and development expenses 20,910 28,189 65,835 87,153 General and administrative expenses 257,404 292,381 706,026 829,516 Sales and marketing expenses 31,888 51,924 93,989 91,164 Total expenses related to stock options 325,231 406,613 914,689 1,097,439 RSUs Cost of revenues — 14,918 — 16,834 Research and development expenses 1,625 14,131 10,724 15,583 General and administrative expenses 12,515 6,668 90,853 7,676 Sales and marketing expenses — 22,939 — 27,447 Total stock-based compensation $ 339,371 $ 465,269 $ 1,016,266 $ 1,164,979 Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 4% and 0% - 8% per annum during the three and nine months ended September 30, 2015 and 2016, respectively. As of September 30, 2016, total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,081,000 and is expected to be recognized over a weighted-average period of 2.1 years.

Common Stock Warrants Outstandi

Common Stock Warrants Outstanding	9 Months Ended
	Sep. 30, 2016
Other Liabilities Disclosure [Abstract]
Common Stock Warrants Outstanding	9. Common Stock Warrants Outstanding On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The summary of equity-classified common stock warrant activity has been adjusted for this reverse stock split as if it had occurred on December 31, 2015. A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2015 784,234 $ 11.19 3.8 Issued 1,163,526 $ 3.90 Exercised — Expired (50,904 ) $ 30.00 Outstanding at September 30, 2016 1,896,856 $ 6.21 4.1 The intrinsic value of equity-classified common stock warrants outstanding and exercisable at September 30, 2016 was zero.

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Loss per Common Share	10. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the nine months ended September 30, 2015 and 2016, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same. On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse stock split as if it had occurred on January 1, 2015. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and nine months ended September 30, 2015 2016 Preferred warrants outstanding (number of common stock equivalents) 529 529 Preferred share RSUs (number of common stock equivalents) 24,384 — Common warrants outstanding 797,579 1,896,856 Common share RSUs 25,752 176,749 Common options outstanding 684,779 926,608 Total anti-dilutive common share equivalents 1,533,023 3,000,742

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 47,331 shares of the Company’s common stock and warrants to purchase up to an aggregate of 47,331 shares of its common stock for total gross proceeds of $177,500 (see Note 3). A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of $19,047 during the nine months ended September 30, 2016 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement. Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A total of $64,020 and $115,236 in rental income was recorded to other income in the Company’s unaudited condensed statements of operations and comprehensive loss during the nine months ended September 30, 2015 and 2016, respectively. Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 58,335 shares of the Company’s common stock and warrants to purchase up to an aggregate of 40,832 shares of its common stock for total gross proceeds to the Company of $175,000. Additionally, a trust affiliated with the Company’s major stockholder, Claire K.T. Reiss, participated in its public offering in May 2016, purchasing 204,758 shares of its common stock and warrants to purchase up to 143,330 shares of its common stock for total gross proceeds to the Company of $614,273 (see Note 3). The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million. The estimated grant date fair value of these warrants of approximately $0.57 per share, or a total of approximately $5.2 million, was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. All warrants sold in this offering Overallotment Options Warrants Stock price $ 0.93 $ 0.93 Exercise price $ 1.0331 $ 1.10 Expected dividend yield 0.00 % 0.00 % Discount rate-bond equivalent yield 0.25 % 1.24 % Expected life (in years) 0.08 5.00 Expected volatility 12.9 % 80.0 % Seven members of the Company’s Board of Directors, including its Chief Executive Officer, and all three of the Company’s other executive officers participated in the Company’s public offering in October 2016, purchasing an aggregate of 534,088 shares of common stock and warrants to purchase up to an aggregate of 534,088 shares of common stock for total gross proceeds to the Company of $587,497. Additionally, a trust affiliated with the Company’s major shareholder, Claire K.T. Reiss, participated in the Company’s public offering in October 2016, purchasing 227,272 shares of its common stock and warrants to purchase up 227,272 shares of its common stock for total gross proceeds to the Company of $249,999. Further, several of the Company’s employees and one of its consultants participated in the Company’s public offering in October 2016, purchasing an aggregate of 79,090 shares of its common stock and warrants to purchase up to an aggregate of 79,090 shares of its common stock for total aggregate gross proceeds to the Company of $86,999. Over the past several years the Company has generated operating losses in all jurisdictions in which it may be subject to income taxes. As a result, the Company has accumulated significant net operating losses and other deferred tax assets. Because of the Company’s history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized. The Company does not expect to report a provision for income taxes until it has a history of earnings, if ever, that would support the realization of its deferred tax assets. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, the Company believes ownership changes likely occurred in both 2015 and 2016. As a result, the Company has estimated that the use of its net operating loss is limited and the remaining net operating loss carryforwards and research and development credits it estimates can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero. On November 4, 2016, the Company voluntarily terminated the common stock purchase agreement that the Company entered into on December 21, 2015, with Aspire Capital. Pursuant to this common stock purchase agreement, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares
The Company and Business Activities	The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended September 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
Fair Value Measurement	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Assumptions Used for Determining Fair Values of Common Stock Warrants	the estimated grant date fair value of $1.72 per share associated with the warrants to purchase 1,163,526 shares of common stock issued in such offering, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 2.70 Exercise price $ 3.90 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.23 % Expected life (in years) 5.00 Expected volatility 90.0 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details: December 31, September 30, 2015 2016 Fixed Assets Machinery and equipment $ 2,518,158 $ 2,707,601 Furniture and office equipment 143,726 143,726 Computer equipment and software 577,898 617,802 Leasehold improvements 514,614 517,968 Financed equipment 914,179 1,457,377 Construction in process 70,815 118,280 4,739,390 5,562,754 Less accumulated depreciation and amortization 3,793,210 4,041,374 Total fixed assets, net $ 946,180 $ 1,521,380 Accrued Liabilities Accrued interest $ 28,981 $ 23,825 Accrued payroll 128,753 301,988 Accrued vacation 307,845 313,825 Accrued bonuses 376,100 318,237 Accrued sales commissions 76,574 97,844 Current portion of deferred rent 31,170 60,475 Accrued other 17,476 27,669 Total accrued liabilities $ 966,899 $ 1,143,863

Capital Lease Obligations (Tabl

Capital Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2016
Capital Lease Obligations [Abstract]
Schedule of Future Minimum Lease Payments for Capital Lease Obligations	The following schedule sets forth the future minimum lease payments, as well as corresponding laboratory equipment maintenance obligations that are not recorded as part of the leased equipment balances within fixed assets or capital lease obligations, outstanding under capital leases and due within each respective year ending December 31, and the present value of the minimum lease payments as of September 30, 2016: Minimum Maintenance Lease Obligation Payments Payments 2016 $ 68,754 $ 6,375 2017 238,287 25,440 2018 190,333 25,434 2019 155,388 24,676 2020 151,400 24,608 Thereafter 374,005 59,471 Total payments 1,178,167 166,004 Less amount representing interest 350,466 — Present value of payments $ 827,701 $ 166,004

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity for Option Awards Granted	A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Vested and unvested expected to vest, December 31, 2015 646,900 $ 15.48 9.0 Outstanding at December 31, 2015 713,659 $ 11.23 9.0 Granted 276,628 $ 2.60 Exercised — Cancelled/forfeited/expired (63,679 ) $ 8.08 Outstanding at September 30, 2016 926,608 $ 8.87 8.7 Vested and unvested expected to vest, September 30, 2016 838,037 $ 9.37 8.1
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions: Stock and exercise prices $1.57 - $4.02 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 0.99% – 1.39% Expected life (in years) 5.13 – 6.08 Expected volatility 80.0% - 90.0%
Schedule of Performance Stock Options Vesting Percentage	Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows: Percentage of Overall Stock Option Grants Subject to Vesting Target Minimum number of accessions processed, billed and collected 13 % Minimum revenues from contracts with pharmaceutical companies 10 % Attainment of a sustainable positive GAAP gross margin 12 % Minimum operating cash on-hand with no more than one interim dilutive equity financing event 15 % Achievement of the Company's 2016 corporate goals 25 % Completion of a Board-approved strategic transaction 25 % Total 100 % Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows: Percentage of Overall RSU Grant Subject to Vesting Target Minimum revenue 25 % Maximum EBITDA loss 15 % Attainment of financial plan for fiscal 2015 20 % Minimum value of strategic agreements 20 % Implementation of four new diagnostic test panels 20 % Total 100 %
Summary of RSU Activity for Awards Granted	A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows: Weighted Number of Average Grant Shares Date Fair Value Vested and unvested expected to vest, December 31, 2015 15,369 $ 14.49 Outstanding at December 31, 2015 25,752 $ 15.12 Granted 165,829 $ 1.96 Vested and issued (4,449 ) $ 16.05 Forfeited (10,383 ) $ 16.05 Outstanding at September 30, 2016 176,749 $ 2.70 Vested and unvested expected to vest, September 30, 2016 172,550 $ 2.71
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the nine months ended September 30, September 30, 2015 2016 2015 2016 Stock Options Cost of revenues $ 15,029 $ 34,119 $ 48,839 $ 89,606 Research and development expenses 20,910 28,189 65,835 87,153 General and administrative expenses 257,404 292,381 706,026 829,516 Sales and marketing expenses 31,888 51,924 93,989 91,164 Total expenses related to stock options 325,231 406,613 914,689 1,097,439 RSUs Cost of revenues — 14,918 — 16,834 Research and development expenses 1,625 14,131 10,724 15,583 General and administrative expenses 12,515 6,668 90,853 7,676 Sales and marketing expenses — 22,939 — 27,447 Total stock-based compensation $ 339,371 $ 465,269 $ 1,016,266 $ 1,164,979

Common Stock Warrants Outstan25

Common Stock Warrants Outstanding (Tables)	9 Months Ended
	Sep. 30, 2016
Equity Classified Warrants [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The summary of equity-classified common stock warrant activity has been adjusted for this reverse stock split as if it had occurred on December 31, 2015. A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2015 784,234 $ 11.19 3.8 Issued 1,163,526 $ 3.90 Exercised — Expired (50,904 ) $ 30.00 Outstanding at September 30, 2016 1,896,856 $ 6.21 4.1

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and nine months ended September 30, 2015 2016 Preferred warrants outstanding (number of common stock equivalents) 529 529 Preferred share RSUs (number of common stock equivalents) 24,384 — Common warrants outstanding 797,579 1,896,856 Common share RSUs 25,752 176,749 Common options outstanding 684,779 926,608 Total anti-dilutive common share equivalents 1,533,023 3,000,742

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2016
Assumptions Used for Determining Fair Values of Common Stock Warrants	the estimated grant date fair value of $1.72 per share associated with the warrants to purchase 1,163,526 shares of common stock issued in such offering, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 2.70 Exercise price $ 3.90 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.23 % Expected life (in years) 5.00 Expected volatility 90.0 %
Overallotment Options, Overallotment Warrants and Non-overallotment Warrants [Member]
Assumptions Used for Determining Fair Values of Common Stock Warrants	The fair values of these overallotment options and all warrants issued in the October 2016 offering were estimated using Black-Scholes valuation models with the following assumptions: Overallotment Options Warrants Stock price $ 0.93 $ 0.93 Exercise price $ 1.0331 $ 1.10 Expected dividend yield 0.00 % 0.00 % Discount rate-bond equivalent yield 0.25 % 1.24 % Expected life (in years) 0.08 5.00 Expected volatility 12.9 % 80.0 %

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail)	Sep. 27, 2016shares	Sep. 30, 2016shares	Dec. 31, 2015shares
Summary Of Significant Accounting Policies [Line Items]
Stockholders equity reverse stock split ratio	0.33
Common stock, shares authorized		150,000,000	40,000,000
Description of reverse stock split		On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares.
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized	40,000,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized	150,000,000

Liquidity and Going Concern U29

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Feb. 13, 2015	Nov. 09, 2016	May 31, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	May 31, 2015	Dec. 31, 2014
Liquidity And Managements Plans [Line Items]
Cash and cash equivalents								$ 678,855	$ 12,541,919	$ 678,855	$ 12,541,919	$ 8,821,329		$ 5,364,582
Accumulated deficit								(169,448,996)		(169,448,996)		(155,236,548)
Net loss								(4,743,076)	$ (4,496,193)	(14,212,448)	(12,332,026)	$ (16,900,000)
Other non-interest bearing liabilities								$ 2,800,000		$ 2,800,000
Unconditional purchase commitment aggregate amount							$ 1,062,500
Unconditional purchase commitment, quarterly payment amount							62,500
Unconditional purchase commitment payment terms										Quarterly
Unconditional purchase commitment period										May 31, 2020
Proceeds from exercise of common stock warrants				$ 9,800,000							$ 9,697,660
Proceeds from gross exercise of common stock warrants outstanding				$ 2,700,000
Exercisable warrant available price per share				$ 4.68
Exercisable warrant available price per share expiration period				2020-02
Issuance of warrants to purchase shares of common stock			1,163,526	400,000
Stock price								$ 2.70		$ 2.70
Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants	$ 564	$ 564			$ 0
Roth Capital Partners, LLC and Feltl [Member] | Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Public offering, number of shares issued		9,100,000
Issuance of warrants to purchase shares of common stock	9,100,000	9,100,000
Stock price		$ 1.10
Proceeds from issuance of common stock		$ 10,000,000
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants			$ 0
Proceeds from gross exercise of common stock warrants outstanding			$ 4,500,000
Exercisable warrant available price per share			$ 3.90
Exercisable warrant available price per share expiration period			2021-05
Minimum public float limit for offering			$ 75,000,000			$ 75,000,000							$ 75,000,000
Proceeds from issuance of common stock, net of issuance costs			$ 4,300,000
Period of limitation to issue variable rate securities			1 year			1 year
Issuance of warrants to purchase shares of common stock			1,163,526
Stock price			$ 3
Proceeds from issuance of common stock			$ 4,600,000
April 2014 Credit Facility [Member]
Liquidity And Managements Plans [Line Items]
Aggregate gross interest-bearing indebtedness								$ 5,300,000		$ 5,300,000
Due within one year								$ 2,200,000		$ 2,200,000
Minimum [Member]
Liquidity And Managements Plans [Line Items]
Unconditional purchase commitment, quarterly payment amount							$ 62,500
Maximum [Member] | Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock	1,365,000	1,365,000
Maximum [Member] | Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price													$ 50,000,000

Sales of Equity Securities - Ad

Sales of Equity Securities - Additional Information (Detail) - USD ($)	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Dec. 21, 2015	Feb. 13, 2015	Feb. 09, 2015	Nov. 09, 2016	May 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	May 31, 2015
Class Of Stock [Line Items]
Stock price									$ 2.70
Purchase of common stock by underwriters to cover overallotments, grant date fair value			$ 2,000,000						$ 7,700,000
Exercise price of warrants			$ 3.90		$ 4.68
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs					$ 9,100,000
Increase in capital shares value						$ 8,800,000			$ 1,400,000
Additional costs incurred prior to, and associated with IPO, beginning of period					$ 300,000
Overallotment issued to underwriter to purchase common stock, period						45 days			45 days
Purchase of common stock by underwriters to cover overallotments, number of shares					400,000
Issuance of warrants to purchase shares of common stock			1,163,526		400,000
Purchase of common stock by underwriters to cover overallotments, per share					$ 3.75				$ 3.75
Common stock, par value					$ 0.0003				$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value					$ 1,600,000				$ 1,600,000
Underwriter cost					200,000
Underwriting discounts					700,000
Non-underwriter costs					300,000
Proceeds from exercise of common stock warrants					9,800,000					$ 9,697,660
Aggregate increase in capital from public offerings					18,600,000
Underwriting cost and discount					$ 900,000
Common stock issuance costs									$ 83,000		$ 42,000
Exercisable warrant available price per share expiration period					2020-02
Common stock, shares issued									8,399,397		6,556,685
Subsequent Event [Member]
Class Of Stock [Line Items]
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 5,200,000	$ 5,200,000
Exercise price of warrants	$ 1.10	$ 1.10
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs	$ 9,400,000
Overallotment issued to underwriter to purchase common stock, period	30 days	30 days
Purchase of common stock by underwriters to cover overallotments, number of shares	627,131	627,131
Purchase of common stock by underwriters to cover overallotments, per share	$ 1.0331	$ 1.0331
Common stock, par value	$ 0.0009	$ 0.0009
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 800,000	$ 800,000
Underwriter cost	600,000
Non-underwriter costs		600,000
Proceeds from exercise of common stock warrants	564	$ 564					$ 0
Underwriting cost and discount	600,000
Increase in capital shares value	$ 8,800,000
Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Maximum number of shares of common stock to be purchase per business day				33,333
Aggregate amount of common stock				$ 15,000,000
Consecutive trading days threshold				10 days
Common stock shares trading volume percentage				30.00%
Percentage of volume weighted average price				97.00%
Common stock, shares issued				55,000
Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock									$ 544,051
Aggregate common stock shares purchase									173,145
Common Stock [Member] | Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued				208,334
Stock price				$ 4.80
Increase in capital shares value				$ 15,000,000
Overallotment issued to underwriter to purchase common stock, period				30 months
Proceeds from issuance of common stock				$ 1,000,000
Maximum [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Purchase of common stock by underwriters to cover overallotments, number of shares	1,365,000	1,365,000
Issuance of warrants to purchase shares of common stock	1,365,000	1,365,000
Minimum [Member] | Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Stock price				$ 1.50
Sale of common stock, closing price per share				$ 1.50
Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Stock price			$ 3
Exercise price of warrants			$ 3.90
Issuance of warrants to purchase shares of common stock			1,163,526
Proceeds from exercise of common stock warrants			$ 0
Minimum public float limit for offering			$ 75,000,000					$ 75,000,000				$ 75,000,000
Period of limitation to issue variable rate securities			1 year					1 year
Placement agent agreement, effective date			Apr. 25, 2016
Securities purchase agreement, effective date			Apr. 29, 2016
Public offering, number of shares issued			1,662,191
Proceeds from issuance of common stock			$ 4,600,000
Increase in capital shares value			4,300,000
Third party costs incurred in connection with offering			300,000
Common stock issuance costs			700,000
Proceeds from gross exercise of common stock warrants outstanding			$ 4,500,000
Exercisable warrant available price per share expiration period			2021-05
Shelf Registration Statement [Member] | Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price												$ 50,000,000
Aegis Capital Corp. and Feltl [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued						2,666,666
Stock price					$ 3.75
Roth Capital Partners, LLC and Feltl [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued		9,100,000
Stock price		$ 1.10
Issuance of warrants to purchase shares of common stock	9,100,000	9,100,000
Proceeds from issuance of common stock		$ 10,000,000

Fair Value Measurement - Other

Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	May 04, 2016	Sep. 30, 2016	Feb. 13, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 2	$ 7.7
Issuance of warrants to purchase shares of common stock	1,163,526		400,000
Warrant exercise price		$ 3.90
Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant exercise price	$ 1.72

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	9 Months Ended
	Sep. 30, 2016$ / shares
Fair Value Disclosures [Abstract]
Stock price	$ 2.70
Exercise price	$ 3.90
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.23%
Expected life (in years)	5 years
Expected volatility	90.00%

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Fixed Assets
Machinery and equipment	$ 2,707,601	$ 2,518,158
Furniture and office equipment	143,726	143,726
Computer equipment and software	617,802	577,898
Leasehold improvements	517,968	514,614
Financed equipment	1,457,377	914,179
Construction in process	118,280	70,815
Total fixed assets, gross	5,562,754	4,739,390
Less accumulated depreciation and amortization	4,041,374	3,793,210
Total fixed assets, net	1,521,380	946,180
Accrued Liabilities
Accrued interest	23,825	28,981
Accrued payroll	301,988	128,753
Accrued vacation	313,825	307,845
Accrued bonuses	318,237	376,100
Accrued sales commissions	97,844	76,574
Current portion of deferred rent	60,475	31,170
Accrued other	27,669	17,476
Total accrued liabilities	$ 1,143,863	$ 966,899

April 2014 Credit Facility - Ad

April 2014 Credit Facility - Additional Information (Detail) - USD ($)	Dec. 31, 2016	May 04, 2016	Feb. 13, 2015	Apr. 30, 2014	Sep. 30, 2016	Dec. 31, 2014	Dec. 31, 2015
Line of Credit Facility [Line Items]
Exercise price of warrants		$ 3.90	$ 4.68
Warrant term		5 years			5 years
Issuance of warrants to purchase shares of common stock, grant date fair value			$ 1,600,000		$ 1,600,000
Minimum [Member]
Line of Credit Facility [Line Items]
Unrestricted cash proceeds from Issuance of equity securities					7,000,000
Oxford Finance LLC [Member]
Line of Credit Facility [Line Items]
Additional final payment to lender					50,000
Oxford Finance LLC [Member] | Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender				17,655
Exercise price of warrants				$ 14.16
Warrant term				10 years
Oxford Finance LLC [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Debt Default limit amount				$ 250,000
Debt default final judgment amount				250,000
Oxford Finance LLC [Member] | First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan				4,898,000
Line Of Credit Facility Fees Amount Payable				$ 50,000
Line of Credit Facility, Interest Rate During Period				7.95%
Percentage of final interest payment due at maturity				5.50%
Total indebtedness and capital lease obligations outstanding					$ 1,200,000
Issuance costs						$ 102,498
Net proceeds from credit facility						4,897,502
Issuance of warrants to purchase shares of common stock, grant date fair value						$ 233,107
Effective annual interest rate					13.87%		11.50%
Oxford Finance LLC [Member] | Scenario One
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period				7.95%
Oxford Finance LLC [Member] | Scenario Two
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period				7.71%
Oxford Finance LLC [Member] | Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Additional final payment to lender	$ 75,000
Two Years [Member] | Oxford Finance LLC [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage				1.00%

Capital Lease Obligations - Add

Capital Lease Obligations - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Capital Lease Obligations [Line Items]
Financed equipment	$ 1,457,377		$ 1,457,377		$ 914,179
Accumulated depreciation related to leased equipment	616,000		$ 616,000		$ 523,000
Lease obligation weighted average effective annual interest rates			13.35%
Lease obligations maturity date on outstanding arrangements range, Start			2017-07
Lease obligations maturity date on outstanding arrangements range, End			2023-05
Present value of minimum lease payment due within one year	255,605		$ 255,605
Capital Lease Equipment [Member]
Capital Lease Obligations [Line Items]
Depreciation expense for the leased equipment	$ 40,000	$ 24,000	$ 93,000	$ 49,000
Minimum [Member] | Capital Lease Equipment [Member]
Capital Lease Obligations [Line Items]
Lease equipment useful life			5 years
Maximum [Member] | Capital Lease Equipment [Member]
Capital Lease Obligations [Line Items]
Lease equipment useful life			7 years

Capital Lease Obligations - Sch

Capital Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Lease Obligations (Detail)	Sep. 30, 2016USD ($)
Capital Lease Obligations [Abstract]
2,016	$ 68,754
2,017	238,287
2,018	190,333
2,019	155,388
2,020	151,400
Thereafter	374,005
Total payments	1,178,167
Less amount representing interest	350,466
Present value of payments	827,701
2,016	6,375
2,017	25,440
2,018	25,434
2,019	24,676
2,020	24,608
Thereafter	59,471
Total payments	166,004
Present value of payments	$ 166,004

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail)

Sep. 27, 2016shares

Jul. 29, 2016$ / sharesshares

Jul. 25, 2016$ / sharesshares

Jul. 06, 2016USD ($)$ / sharesshares

Feb. 29, 2016$ / sharesshares

Aug. 31, 2015$ / sharesshares

Jun. 12, 2014$ / sharesshares

Sep. 30, 2016USD ($)shares

Sep. 30, 2015

Sep. 30, 2016USD ($)Plan$ / sharesshares

Sep. 30, 2015

Dec. 31, 2015shares

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stockholders equity reverse stock split ratio

0.33

Number of equity incentive plans | Plan

2

Total Shares Outstanding

926,608

926,608

713,659

Number of Shares, Granted

276,628

Unrecognized stock-based compensation expense, weighted-average recognition period

2 years 1 month 6 days

Stock Options [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Intrinsic value of options outstanding | $

$ 0

$ 0

Intrinsic value of options vested and unvested expected to vest | $

0

0

Intrinsic value of options exercisable | $

0

$ 0

Option awards assumptions, method used

Black-Scholes pricing model

Weighted-average estimated fair value of options granted | $ / shares

$ 1.86

Percentage of Overall Stock Grant Subject to Vesting

100.00%

RSUs [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Weighted-average estimated fair value of options granted | $ / shares

$ 16.05

Percentage of Overall Stock Grant Subject to Vesting

100.00%

Vesting period

1 year

Intrinsic value shares, RSUs outstanding | $

277,496

$ 277,496

Intrinsic value amount, RSUs unvested and vested expected to vest | $

270,904

$ 270,904

Issuance of restricted stock units

14,832

165,829

Total RSUs forfeited

10,383

RSUs [Member] | Chief Executive Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of vested shares issued

4,449

Stock Options and RSUs [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Unrecognized stock-based compensation expense, stock options | $

$ 2,081,000

$ 2,081,000

2013 Equity Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stockholders equity reverse stock split ratio

0.33

2013 Equity Incentive Plan [Member] | Stock Options [Member] | Chief Executive Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Weighted-average estimated fair value of options granted | $ / shares

$ 2.87

$ 4.40

Number of Shares, Granted

33,333

33,333

2013 Equity Incentive Plan [Member] | RSUs [Member] | Chief Financial Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Percentage of Overall Stock Grant Subject to Vesting

100.00%

Vesting period

1 year

Restricted stock units, grant date fair value | $ / shares

$ 1.95

Restricted stock unit award, shares

25,000

2013 Equity Incentive Plan [Member] | Retention RSUs [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

1 year

Restricted stock units, grant date fair value | $ / shares

$ 1.86

Restricted stock units, grant date fair value | $

$ 108,498

2013 Equity Incentive Plan [Member] | Retention RSUs [Member] | Chief Executive Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Issuance of restricted stock units

25,000

2013 Equity Incentive Plan [Member] | Retention RSUs [Member] | Executive Officers [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Issuance of restricted stock units

58,332

2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

1,022,955

1,022,955

Stock options and RSUs issued

978,358

Total Shares Outstanding

978,358

978,358

Common stock, shares authorized

3,115

3,115

2013 Equity Incentive Plan [Member] | Inducement shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

333,333

333,333

Stock options and RSUs issued

124,999

Total Shares Outstanding

124,999

124,999

Common stock, shares authorized

208,334

208,334

2013 Equity Incentive Plan [Member] | Options Vesting on One Year Anniversary [Member] | Chief Financial Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

66,666

Weighted-average estimated fair value of options granted | $ / shares

$ 1.45

Percentage of Overall Stock Grant Subject to Vesting

25.00%

Vesting period

1 year

Stock option units remaining vesting period on Equal monthly basis

3 years

2013 Equity Incentive Plan [Member] | Options Vesting on Performance Achievement [Member] | Chief Financial Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

33,333

Weighted-average estimated fair value of options granted | $ / shares

$ 1.26

2013 Equity Incentive Plan [Member] | Pre-reverse Stock Split [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

1,000,000

2013 Equity Incentive Plan [Member] | Post-reverse Stock Split [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

333,333

Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Estimated forfeitures rate

8.00%

4.00%

8.00%

4.00%

Maximum [Member] | 2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

3,068,865

Maximum [Member] | 2013 Equity Incentive Plan [Member] | Inducement shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

1,000,000

Minimum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Estimated forfeitures rate

0.00%

0.00%

0.00%

0.00%

Minimum [Member] | 2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

1,022,955

Minimum [Member] | 2013 Equity Incentive Plan [Member] | Inducement shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized

333,333

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Vested and unvested expected to vest, Beginning Balance	646,900
Number of Shares Outstanding, Beginning Balance	713,659
Number of Shares, Granted	276,628
Number of Shares, Cancelled/forfeited/expired	(63,679)
Number of Shares Outstanding, Ending Balance	926,608	713,659
Number of Shares, Vested and unvested expected to vest, Ending Balance	838,037	646,900
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Beginning Balance	$ 15.48
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	11.23
Weighted Average Exercise Price Per Share, Granted	2.60
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	8.08
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	8.87	$ 11.23
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 9.37	$ 15.48
Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 1 month 6 days	9 years
Average Remaining Contractual Term in Years, Outstanding	8 years 8 months 12 days	9 years

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	9 Months Ended
	Sep. 30, 2016$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 1.57
Discount rate-bond equivalent yield	0.99%
Expected life (in years)	5 years 1 month 17 days
Expected volatility	80.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 4.02
Discount rate-bond equivalent yield	1.39%
Expected life (in years)	6 years 29 days
Expected volatility	90.00%

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail)	9 Months Ended
	Sep. 30, 2016
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Stock Options [Member] | Minimum Number of Accessions Processed, Billed and Collected [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	13.00%
Stock Options [Member] | Minimum Revenues from Contracts with Pharmaceutical Companies [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	10.00%
Stock Options [Member] | Attainment of a Sustainable Positive GAAP Gross Margin [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	12.00%
Stock Options [Member] | Minimum Operating Cash on-Hand with no More than One Interim Dilutive Equity Financing Event [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Stock Options [Member] | Achievement of the Company's 2016 Corporate Goals [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
Stock Options [Member] | Completion of a Board-approved Strategic Transaction [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
RSUs [Member] | Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member] | Maximum EBITDA Loss [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
RSUs [Member] | Attainment of Financial Plan for Fiscal 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] | Minimum Value of Strategic Agreements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] | Implementation of Four New Diagnostic Test Panels [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%

Stock-based Compensation - Su41

Stock-based Compensation - Summary of RSU Activity for Awards Granted (Detail) - RSUs [Member] - $ / shares	Jun. 12, 2014	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Vested and unvested expected to vest, Beginning Balance		15,369
Number of Shares Outstanding, Beginning Balance		25,752
Number of Shares, Granted	14,832	165,829
Number of share, Vested and issued		(4,449)
Number of share, Forfeited		(10,383)
Number of Shares Outstanding, Ending Balance		176,749
Number of Shares, Vested and unvested expected to vest, Ending Balance		172,550
Weighted Average Grand Date Fair Value, Vested unvested expected to vest, Beginning Balance		$ 14.49
Weighted Average Grand Date Fair Value, Outstanding, Beginning Balance		15.12
Weighted Average Grand Date Fair Value, Granted		1.96
Weighted Average Grand Date Fair Value, Vested and issued		16.05
Weighted Average Grand Date Fair Value, Forfeited		16.05
Weighted Average Grand Date Fair Value, Outstanding, Ending Balance		2.70
Weighted Average Grand Date Fair Value, Vested unvested expected to vest, Ending Balance		$ 2.71

Stock-based Compensation - Effe

Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 406,613	$ 325,231	$ 1,097,439	$ 914,689
Stock Options [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	34,119	15,029	89,606	48,839
Stock Options [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	28,189	20,910	87,153	65,835
Stock Options [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	292,381	257,404	829,516	706,026
Stock Options [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	51,924	31,888	91,164	93,989
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	465,269	339,371	1,164,979	1,016,266
RSUs [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	14,918		16,834
RSUs [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	14,131	1,625	15,583	10,724
RSUs [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	6,668	$ 12,515	7,676	$ 90,853
RSUs [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 22,939		$ 27,447

Common Stock Warrants Outstan43

Common Stock Warrants Outstanding - Additional Information (Detail)	Sep. 27, 2016	Sep. 30, 2016USD ($)
Warrants And Rights Note Disclosure [Abstract]
Reverse stock split of common shares outstanding	0.33
Common stock warrants exercisable, intrinsic value		$ 0
Common stock warrants outstanding, intrinsic value		$ 0

Common Stock Warrants Outstan44

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	784,234
Number of Shares, Issued	1,163,526
Number of Shares, Expired	(50,904)
Number of Shares, Outstanding, Ending Balance	1,896,856	784,234
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 11.19
Weighted Average Exercise Price Per Share, Issued	3.90
Weighted Average Exercise Price Per Share, Expired	30
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 6.21	$ 11.19
Average Remaining Contractual Term (in years)	4 years 1 month 6 days	3 years 9 months 18 days

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Detail)	Sep. 27, 2016
Earnings Per Share [Abstract]
Reverse stock split of common shares outstanding	0.33

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	3,000,742	1,533,023	3,000,742	1,533,023
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	1,896,856	797,579	1,896,856	797,579
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	529	529	529	529
Preferred Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		24,384		24,384
Common Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	176,749	25,752	176,749	25,752
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	926,608	684,779	926,608	684,779

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 29, 2016	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Unconditional purchase commitment aggregate amount	$ 1,062,500
Unconditional purchase commitment, quarterly payment amount	$ 62,500
Unconditional purchase commitment payment terms		Quarterly
Unconditional purchase commitment period		May 31, 2020

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	May 04, 2016USD ($)Directorshares	Feb. 09, 2015USD ($)shares	Sep. 30, 2016USD ($)ft²	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)ft²	Sep. 30, 2015USD ($)	Feb. 13, 2015shares
Related Party Transaction [Line Items]
Issuance of warrants to purchase shares of common stock | shares	1,163,526						400,000
Rental income			$ 38,412	$ 38,412	$ 115,236	$ 64,020
Director [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares	58,335	47,331
Issuance of warrants to purchase shares of common stock | shares	40,832	47,331
Proceeds from issuance of common stock	$ 175,000	$ 177,500
Number of members of board of directors | Director	3
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs					$ 19,047
Nonexecutive [Member]
Related Party Transaction [Line Items]
Lease agreement date of commencement					Mar. 30, 2015
Leased facility, rent expense per month					$ 12,804
Lease facility, refundable security deposit amount			$ 12,804		$ 12,804
Lease expiration date					Jul. 31, 2015
Nonexecutive [Member] | San Diego California Facility [Member]
Related Party Transaction [Line Items]
Leased facility, expansion of original premises | ft²			9,849		9,849
Major Stockholder, Claire K.T. Reiss [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares	204,758
Issuance of warrants to purchase shares of common stock | shares	143,330
Proceeds from issuance of common stock	$ 614,273

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Oct. 19, 2016USD ($)$ / sharesshares	Oct. 14, 2016USD ($)DirectorConsultant$ / sharesshares	May 04, 2016USD ($)Director$ / sharesshares	Dec. 21, 2015USD ($)$ / sharesshares	Feb. 13, 2015USD ($)$ / sharesshares	Feb. 09, 2015USD ($)shares	Nov. 09, 2016USD ($)	Sep. 30, 2016USD ($)$ / shares	Sep. 30, 2015USD ($)	Dec. 31, 2015$ / shares
Subsequent Event [Line Items]
Issuance of warrants to purchase shares of common stock | shares			1,163,526		400,000
Stock price | $ / shares								$ 2.70
Purchase of common stock by underwriters to cover overallotments, grant date fair value			$ 2,000,000					$ 7,700,000
Overallotment issued to underwriter to purchase common stock, period						45 days		45 days
Purchase of common stock by underwriters to cover overallotments, number of shares | shares					400,000
Purchase of common stock by underwriters to cover overallotments, per share | $ / shares					$ 3.75			$ 3.75
Common stock, par value | $ / shares					$ 0.0003			$ 0.0001		$ 0.0001
Proceeds from exercise of common stock warrants					$ 9,800,000				$ 9,697,660
Issuance of warrants to purchase shares of common stock, grant date fair value					$ 1,600,000			$ 1,600,000
Exercise price of warrants | $ / shares			$ 3.90		$ 4.68
Underwriters discount and additional costs paid					$ 900,000
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs					9,100,000
Underwriter cost					200,000
Non-underwriter costs					$ 300,000
Increase in capital shares value						$ 8,800,000		$ 1,400,000
Common Stock [Member] | Aspire Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares				208,334
Stock price | $ / shares				$ 4.80
Proceeds from issuance of common stock				$ 1,000,000
Overallotment issued to underwriter to purchase common stock, period				30 months
Increase in capital shares value				$ 15,000,000
Common stock purchase agreement termination date								Nov. 4, 2016
Director [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares			58,335			47,331
Issuance of warrants to purchase shares of common stock | shares			40,832			47,331
Proceeds from issuance of common stock			$ 175,000			$ 177,500
Number of members of board of directors | Director			3
Major Stockholder, Claire K.T. Reiss [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares			204,758
Issuance of warrants to purchase shares of common stock | shares			143,330
Proceeds from issuance of common stock			$ 614,273
Subsequent Event [Member]
Subsequent Event [Line Items]
Estimated grant date fair value of warrants | $ / shares	$ 0.57	$ 0.57
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 5,200,000	$ 5,200,000
Overallotment issued to underwriter to purchase common stock, period	30 days	30 days
Purchase of common stock by underwriters to cover overallotments, number of shares | shares	627,131	627,131
Purchase of common stock by underwriters to cover overallotments, per share | $ / shares	$ 1.0331	$ 1.0331
Common stock, par value | $ / shares	$ 0.0009	$ 0.0009
Proceeds from exercise of common stock warrants	$ 564	$ 564					$ 0
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 800,000	$ 800,000
Exercise price of warrants | $ / shares	$ 1.10	$ 1.10
Class of warrant or rights, term	5 years	5 years
Number of consultants | Consultant		1
Underwriters discount and additional costs paid	$ 600,000
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs	9,400,000
Increase in capital shares value	8,800,000
Underwriter cost	$ 600,000
Non-underwriter costs		$ 600,000
Subsequent Event [Member] | Director [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares		534,088
Issuance of warrants to purchase shares of common stock | shares		534,088
Proceeds from issuance of common stock		$ 587,497
Number of members of board of directors | Director		3
Subsequent Event [Member] | Director [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Number of members of board of directors | Director		7
Subsequent Event [Member] | Major Stockholder, Claire K.T. Reiss [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares		227,272
Issuance of warrants to purchase shares of common stock | shares		227,272
Proceeds from issuance of common stock		$ 249,999
Subsequent Event [Member] | Consultants [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares		79,090
Issuance of warrants to purchase shares of common stock | shares		79,090
Proceeds from issuance of common stock		$ 86,999
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Issuance of warrants to purchase shares of common stock | shares	1,365,000	1,365,000
Purchase of common stock by underwriters to cover overallotments, number of shares | shares	1,365,000	1,365,000
Subsequent Event [Member] | Roth Capital Partners, LLC and Feltl [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares		9,100,000
Issuance of warrants to purchase shares of common stock | shares	9,100,000	9,100,000
Stock price | $ / shares		$ 1.10
Proceeds from issuance of common stock		$ 10,000,000

Subsequent Events - Assumptions

Subsequent Events - Assumptions Used for Determining Fair Values of Overallotment Options, Overallotment Warrants and Non-overallotment Warrants Issued (Detail) - $ / shares	Oct. 14, 2016	Sep. 30, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price		$ 2.70
Exercise price		$ 3.90
Expected dividend yield		0.00%
Discount rate-bond equivalent yield		1.23%
Expected life (in years)		5 years
Expected volatility		90.00%
Subsequent Event [Member] | Overallotment Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 0.93
Exercise price	$ 1.0331
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	0.25%
Expected life (in years)	29 days
Expected volatility	12.90%
Subsequent Event [Member] | Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 0.93
Exercise price	$ 1.10
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.24%
Expected life (in years)	5 years
Expected volatility	80.00%